References

Filters: Reilley-2013 is   [Clear All Filters]
B
Brown RS, Hezode C, Wang S, et al. Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1-6 infection and compensated cirrhosis: the EXPEDITION-8 study [Abstract LB-7]. The Liver Meeting. 2018.
Brown RS, Buti M, Rodrigues L, et al. Efficacy and safety of 8-week glecaprevir/pibrentasvir in treatment-naive patients with chronic hepatitis c virus genotype 1, 2, 3, 4, 5, or 6 infection and compensated cirrhosis: EXPEDITION-8 complete results [abstract LP9]. Presented at Liver Meeting, 2019; November 8-12. 2019.
Brown RS, O'Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016;22(1):24-33.
Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase?. Sex Transm Infect. 2004;80(4):326-327.
Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013;57(Suppl 2):S56-S61.
Bruix J, Sherman M, AASLD . Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-1022.
Bruneau J, Zang G, Abrahamowicz M, Jutras-Aswad D, Daniel M, Roy E. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. Clin Infect Dis. 2014;58(6):755-761.
National Academies of Sciences, Committee on a National Strategy for the Elimination of Hepatitis B and C, Board on Population Health and Public Health Practice: A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. Washington, D.C.: National Academies Press; 2017.
Burton MJ, Voluse AC, Anthony V. Integrating comprehensive hepatitis C virus care within a residential substance use disorder treatment program. J Subst Abuse Treat. 2019;(98):9-14. doi:10.1016/j.jsat.2018.11.008.
Bushway SD. The problem of prisoner (re)entry. Contemp Sociol. 2006;35(6):562-565.
Butt AA, McGinnis K, Skanderson M, Justice AC. A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans. AIDS Res Hum Retroviruses. 2011;27(9):973-979.
C
Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state medicaid programs. Ann Intern Med. 2015;163(3):226-228.
Carrat F, Fontaine H, Dorival C. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453-1464. doi:10.1016/S0140-6736(18)32111-1.
Casiraghi MAntonietta, De Paschale M, Romanò L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004;39(1):90-96.
Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350.
Castera L, Sebastiani G, Le BB, de Ledinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010;52(2):191-198.
Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6):1293-1302.
Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr. 2001;33(5):570-575.
Centers for Disease Control and Prevention (CDC). Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60(28):945-950.
Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50(RR-5):1-43.
Top